Marksans Pharma Limited (MARKSANS) — Announcement | 26 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Company receives Crisil ESG score of 56
💡 Investor Takeaway
The ESG score offers a standardized measure of Marksans Pharma's sustainability performance for investor evaluation.

Marksans Pharma announced it received a Crisil ESG rating of 56 for fiscal 2026, reflecting its environmental, social, and governance performance. The score is based on publicly available data and is accessible via BSE's website. This rating provides transparency on the company's sustainability practices for investors.

📄 View Original Announcement (PDF)

About Marksans Pharma Limited (MARKSANS)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹14,612.26 Cr P/E: 28.3 ROE: 17.2% ROCE: 23.4% Div Yield: 0.28%

View full MARKSANS stock details →

📡 Get AI alerts when MARKSANS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MARKSANS — Free

📊 More MARKSANS filings

See all MARKSANS filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MARKSANS files new disclosures

Track MARKSANS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MARKSANS — Free

Free account · 2 AI queries/day